-
1
-
-
0036322130
-
Diagnosis and treatment of autoimmune hepatitis
-
Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.
-
(2002)
Hepatology
, vol.36
, pp. 479-497
-
-
Czaja, A.J.1
Freese, D.K.2
-
3
-
-
77952711598
-
Diagnosis and management of autoimmune hepatitis
-
Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
-
(2010)
Hepatology
, vol.51
, pp. 2193-2213
-
-
Manns, M.P.1
Czaja, A.J.2
Gorham, J.D.3
-
4
-
-
0028656460
-
Cyclosporine in the management of corticosteroid-resistant type i autoimmune chronic active hepatitis
-
Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-7.
-
(1994)
J Hepatol
, vol.21
, pp. 1040-1047
-
-
Sherman, K.E.1
Narkewicz, M.2
Pinto, P.C.3
-
5
-
-
0029024492
-
Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial
-
Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 771-6.
-
(1995)
Am J Gastroenterol
, vol.90
, pp. 771-776
-
-
Van Thiel, D.H.1
Wright, H.2
Carroll, P.3
-
6
-
-
0030034461
-
The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine
-
Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996; 110: 271-4.
-
(1996)
Gastroenterology
, vol.110
, pp. 271-274
-
-
Pratt, D.S.1
Flavin, D.P.2
Kaplan, M.M.3
-
7
-
-
8544229063
-
Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - Report of three cases
-
Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol 1997; 35: 571-578.
-
(1997)
Z Gastroenterol
, vol.35
, pp. 571-578
-
-
Kanzler, S.1
Gerken, G.2
Dienes, H.P.3
Meyer Zum Buschenfelde, K.H.4
Lohse, A.W.5
-
8
-
-
0032403227
-
Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate
-
Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29: 990-3.
-
(1998)
J Hepatol
, vol.29
, pp. 990-993
-
-
Burak, K.W.1
Urbanski, S.J.2
Swain, M.G.3
-
9
-
-
44649191187
-
The use of budesonide in the treatment of autoimmune hepatitis in Canada
-
Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008; 22: 388-92.
-
(2008)
Can J Gastroenterol
, vol.22
, pp. 388-392
-
-
Zandieh, I.1
Krygier, D.2
Wong, V.3
-
10
-
-
0033845138
-
Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine
-
Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-5.
-
(2000)
J Hepatol
, vol.33
, pp. 371-375
-
-
Richardson, P.D.1
James, P.D.2
Ryder, S.D.3
-
11
-
-
3042646320
-
Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy
-
Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321-6.
-
(2004)
Can J Gastroenterol
, vol.18
, pp. 321-326
-
-
Devlin, S.M.1
Swain, M.G.2
Urbanski, S.J.3
Burak, K.W.4
-
13
-
-
33746961890
-
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Esults of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
-
Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: esults of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2793-2806
-
-
Cohen, S.B.1
Emery, P.2
Greenwald, M.W.3
-
14
-
-
79955996011
-
Rituximab therapy for autoimmune haematological diseases
-
Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med 2011; 22: 220-9.
-
(2011)
Eur J Intern Med
, vol.22
, pp. 220-229
-
-
Barcellini, W.1
Zanella, A.2
-
15
-
-
77953264702
-
Innovative uses of rituximab in dermatology
-
Carr DR, Heffernan MP. Innovative uses of rituximab in dermatology. Dermatol Clin 2010; 28: 547-57.
-
(2010)
Dermatol Clin
, vol.28
, pp. 547-557
-
-
Carr, D.R.1
Heffernan, M.P.2
-
16
-
-
84878917142
-
B cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid
-
In press)
-
Myers RP SA, Swain MG, Lee SS, Shaheen AAM, Burak KW. B cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol 2013 (In press).
-
(2013)
Am J Gastroenterol
-
-
Myers, R.P.S.A.1
Swain, M.G.2
Lee, S.S.3
Shaheen, A.A.M.4
Burak, K.W.5
-
17
-
-
84863072278
-
Biochemical and immunological effects of rituximab in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid
-
Tsuda M, Moritoki Y, Lian ZX, et al. Biochemical and immunological effects of rituximab in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid. Hepatology 2012: 55: 512-21.
-
(2012)
Hepatology
, vol.55
, pp. 512-521
-
-
Tsuda, M.1
Moritoki, Y.2
Lian, Z.X.3
-
18
-
-
39049095216
-
Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response
-
Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007; 47: 1119-28.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 1119-1128
-
-
Breedveld, F.1
Agarwal, S.2
Yin, M.3
-
19
-
-
77955895130
-
B-cell targeted therapies in human autoimmune diseases: An updated perspective
-
Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: An updated perspective. Immunol Rev 2010; 237: 264-83.
-
(2010)
Immunol Rev
, vol.237
, pp. 264-283
-
-
Townsend, M.J.1
Monroe, J.G.2
Chan, A.C.3
-
20
-
-
45249085670
-
Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells
-
Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells. Clin Immunol 2008; 127: 280-5.
-
(2008)
Clin Immunol
, vol.127
, pp. 280-285
-
-
Liossis, S.N.1
Sfikakis, P.P.2
-
21
-
-
0032718310
-
International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis
-
Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
-
(1999)
J Hepatol
, vol.31
, pp. 929-938
-
-
Alvarez, F.1
Berg, P.A.2
Bianchi, F.B.3
-
22
-
-
37248999499
-
Rituximab treatment of idiopathic membranous nephropathy
-
Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73: 117-25.
-
(2008)
Kidney Int
, vol.73
, pp. 117-125
-
-
Fervenza, F.C.1
Cosio, F.G.2
Erickson, S.B.3
-
23
-
-
0028806153
-
Chronic hepatitis. An update on terminology and reporting
-
Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.
-
(1995)
Am J Surg Pathol
, vol.19
, pp. 1409-1417
-
-
Batts, K.P.1
Ludwig, J.2
-
24
-
-
33745323050
-
Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B
-
Xu D, Fu J, Jin L, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-47.
-
(2006)
J Immunol
, vol.177
, pp. 739-747
-
-
Xu, D.1
Fu, J.2
Jin, L.3
-
25
-
-
55549108735
-
Validation of the fatigue severity scale in a Swiss cohort
-
Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the fatigue severity scale in a Swiss cohort. Sleep 2008; 31: 1601-7.
-
(2008)
Sleep
, vol.31
, pp. 1601-1607
-
-
Valko, P.O.1
Bassetti, C.L.2
Bloch, K.E.3
Held, U.4
Baumann, C.R.5
-
26
-
-
77951974444
-
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease
-
Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 1133-1139
-
-
Afif, W.1
Loftus Jr., E.V.2
Faubion, W.A.3
-
27
-
-
33646809309
-
Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: Case report and review of literature
-
Santos ES, Arosemena LR, Raez LE, O'Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: Case report and review of literature. Liver Int 2006; 26: 625-9.
-
(2006)
Liver Int
, vol.26
, pp. 625-629
-
-
Santos, E.S.1
Arosemena, L.R.2
Raez, L.E.3
O'Brien, C.4
Regev, A.5
-
28
-
-
53749095755
-
Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis
-
Evans JT, Shepard MM, Oates JC, Self SE, Reuben A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol 2008; 42: 862-3.
-
(2008)
J Clin Gastroenterol
, vol.42
, pp. 862-863
-
-
Evans, J.T.1
Shepard, M.M.2
Oates, J.C.3
Self, S.E.4
Reuben, A.5
-
29
-
-
78751469089
-
A case of autoimmune hepatitis treated with rituximab
-
Barth E, Clawson J. A case of autoimmune hepatitis treated with rituximab. Case Rep Gastroenterol 2010; 4: 502-9.
-
(2010)
Case Rep Gastroenterol
, vol.4
, pp. 502-509
-
-
Barth, E.1
Clawson, J.2
-
30
-
-
77956643943
-
A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis
-
Ferri S, Longhi MS, De Molo C, et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010; 52: 999-1007.
-
(2010)
Hepatology
, vol.52
, pp. 999-1007
-
-
Ferri, S.1
Longhi, M.S.2
De Molo, C.3
-
31
-
-
33646052605
-
Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis
-
Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006; 176: 4484-91.
-
(2006)
J Immunol
, vol.176
, pp. 4484-4491
-
-
Longhi, M.S.1
Hussain, M.J.2
Mitry, R.R.3
-
33
-
-
51649091745
-
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
-
Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008; 112: 1147-50.
-
(2008)
Blood
, vol.112
, pp. 1147-1150
-
-
Stasi, R.1
Cooper, N.2
Del Poeta, G.3
-
34
-
-
33947118656
-
Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis
-
Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007; 123: 66-73.
-
(2007)
Clin Immunol
, vol.123
, pp. 66-73
-
-
Sfikakis, P.P.1
Souliotis, V.L.2
Fragiadaki, K.G.3
Moutsopoulos, H.M.4
Boletis, J.N.5
Theofilopoulos, A.N.6
-
35
-
-
85056071609
-
Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis
-
Feuchtenberger M, Muller S, Roll P, et al. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J 2008; 2: 81-8.
-
(2008)
Open Rheumatol J
, vol.2
, pp. 81-88
-
-
Feuchtenberger, M.1
Muller, S.2
Roll, P.3
-
36
-
-
77955655056
-
Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases
-
Koyabu M, Uchida K, Miyoshi H, et al. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J Gastroenterol 2010; 45: 732-41.
-
(2010)
J Gastroenterol
, vol.45
, pp. 732-741
-
-
Koyabu, M.1
Uchida, K.2
Miyoshi, H.3
-
37
-
-
79958073303
-
Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases
-
Tacke F, Zimmermann HW, Berres ML, Trautwein C, Wasmuth HE. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver Int 2011; 31: 840-9.
-
(2011)
Liver Int
, vol.31
, pp. 840-849
-
-
Tacke, F.1
Zimmermann, H.W.2
Berres, M.L.3
Trautwein, C.4
Wasmuth, H.E.5
-
38
-
-
0035111193
-
Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes
-
Nishioji K, Okanoue T, Itoh Y, et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 2001; 123: 271-9.
-
(2001)
Clin Exp Immunol
, vol.123
, pp. 271-279
-
-
Nishioji, K.1
Okanoue, T.2
Itoh, Y.3
-
39
-
-
0034939844
-
Overexpression of interferon gamma-inducible protein 10 in the liver of patients with type i autoimmune hepatitis identified by suppression subtractive hybridization
-
Nagayama K, Enomoto N, Miyasaka Y, et al. Overexpression of interferon gamma-inducible protein 10 in the liver of patients with type I autoimmune hepatitis identified by suppression subtractive hybridization. Am J Gastroenterol 2001; 96: 2211-7.
-
(2001)
Am J Gastroenterol
, vol.96
, pp. 2211-2217
-
-
Nagayama, K.1
Enomoto, N.2
Miyasaka, Y.3
|